U.S. Healthcare Services Stock News

Newsmax (NMAX) stock has drawn attention after a recent move that left its one day return down 3.4%, even as the month return sits at 34.8% and the past 3 months at 21.4%. At a latest share price of $10.39, Newsmax has seen a sharp 30 day share price return of 34.8% and a year to date share price return of 31.9%, even though the 1 year total shareholder return is down 25.6%. This suggests that short term momentum has picked up while longer term holders have lagged. Scan beyond Newsmax and...

Toll Brothers (TOL) stock is in focus after a series of new luxury community announcements across Texas, Pennsylvania, Georgia, California, Nevada, and New York, highlighting active deployment of its homebuilding platform. The recent luxury community launches arrive after a soft patch in Toll Brothers share price, which is down 7.04% over the past week and 3.89% over the past month, although the 3-year total shareholder return of 81.35% and 5-year total shareholder return of 132.87% point to...

Packaging Corporation of America (PKG) has drawn investor attention after recent trading left the stock down about 7% over the past month, even as total return over the past 3 months remains slightly positive. At a share price of $229.12, Packaging Corporation of America has seen short-term momentum fade, with the 7-day share price return down 7.07% and the 30-day share price return down 6.80%. This is despite the year-to-date share price return of 8.53% and the 5-year total shareholder...

Ultragenyx Pharmaceutical (RARE) stock is in focus after the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS, the company’s first gene therapy and a new treatment option for glycogen storage disease type Ia. At a share price of $25.81, Ultragenyx Pharmaceutical has a 90 day share price return of 15.17%, while the 1 year total shareholder return has declined 19.42%. Recent GENGLYCOS news appears to be improving momentum after several years of weaker overall...

The U.S. Food and Drug Administration has approved Pasatru for adults with fibrodysplasia ossificans progressiva, giving Regeneron Pharmaceuticals (REGN) another rare disease therapy that investors can now factor into the companys product mix. Regeneron Pharmaceuticals' share price has climbed 33.1% over the past 90 days and 8.0% over the past month, while the 1-year total shareholder return of 43.3% points to strong recent gains as investors weigh the Pasatru approval alongside the ongoing...

Best Buy (BBY) is back in focus after a stronger than expected quarter, a raised full year revenue outlook, refreshed leadership and updates on capital returns through share repurchases and a confirmed quarterly dividend. Best Buy's latest earnings, higher full year revenue guidance, and confirmation of buybacks and the dividend have come alongside a 15.2% 90 day share price return and a 19.44% year to date share price return, although the 5 year total shareholder return is slightly negative...

CBIZ stock has delivered a 61.5% gain over the past 5 years, yet its current valuation signals are more muted and point to a mixed picture rather than a clear bargain or clear overvaluation. Recent returns over shorter periods have been softer, which raises the question of whether the earlier run has already priced in much of the good news. The 61.5% return over 5 years suggests CBIZ has rewarded patient shareholders, even though the ride has included periods of weaker performance. Future...

Bond markets are back in the spotlight, with higher government yields, rising borrowing costs and renewed inflation worries reshaping where investors look for returns and resilience. That shift is creating fresh risks for some stocks and fresh potential for others that are more closely tied to bond income. This article unpacks the recent news shock and walks through three insurers that are especially exposed to these cross currents right now. The insurers highlighted below are just a starting...

Wix.com stock has seen a sharp setback over the past few years, yet current valuation checks still suggest the shares may be pricing in more pessimism than the fundamentals imply. After a recent rebound, investors are weighing a weak multi year share price record against signals that the stock screens cheap on several measures. Over the last 5 years, Wix.com has delivered a decline of 61.6% which puts the recent bounce in a very different light for long term holders. Future growth in...

Earlier in 2026, Absci Corporation advanced clinical testing of an injection-based therapy for pattern hair loss, using just two to three doses over six months in a field that has seen little therapeutic change since the 1990s. The company’s focus on a low-frequency dosing regimen for a long-underserved condition is drawing attention because regulatory filings are not expected until at least 2027, yet interest is already building around the potential treatment model. Next, we’ll explore how...

Nike recently expanded its Nike Strength Pro Equipment Line with a new customizable Power Rack ecosystem, now installed at elite facilities including the Arthur M. Blank U.S. Soccer National Training Center, USC’s Bloom Football Performance Center, and the Kaiser Permanente Performance Center for the Portland Fire and Portland Thorns. At the same time, Nike is pursuing an inventory cleanup that it expects will reduce fiscal 2027 revenue while aiming to support healthier margins and a more...

BridgeBio Pharma has delivered a strong gain of 158.5% over the past three years, yet its current valuation screens as only a mixed picture rather than clearly cheap or clearly expensive. For you as an investor, that creates a question about how much of the recent clinical and access progress around acoramidis is already reflected in the share price. The 158.5% return over three years highlights how much optimism has already built into BridgeBio Pharma, which can limit the room for further...

PTC Therapeutics stock has delivered strong share price gains over the past few years, yet current valuation checks suggest investors are paying a premium rather than accessing an obvious bargain. The recent share price around US$70.56 comes with a mixed overall value score and a market multiple profile that leans expensive. PTC Therapeutics has returned about 81.2% over the past 3 years, which puts recent pullbacks into context as part of a strong multi year run. New Sephience data for...

How GEO Group Stock Has Been Trading Recently GEO Group (GEO) has drawn fresh attention after a period of mixed share price moves, with the stock down about 4% in the past day and 5% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of about 29%. Year to date, GEO Group has returned about 92%, with the total return over the past year at roughly 46%. For context, GEO Group has pulled back over the past week but still shows strong momentum...

International Bancshares has delivered a strong 5 year run for shareholders, yet the current valuation picture is more mixed, with recent share price softness and only a moderate value score keeping expectations in check. The stock has returned about 90.2% over 5 years, which suggests long term holders have already captured a sizeable gain. For a regional banking group like International Bancshares, the key support for valuation can come from steady credit quality and funding costs, while a...

In August 2026, Keysight Technologies appointed Scott Reese, a veteran software and industrial technology executive, to its Board and announced that AttoTude Inc. had expanded its use of Keysight EDA software to manage its full IC design workflow, cutting design cycles to under six weeks with consistent first-pass silicon success across advanced RF, sub-THz, and THz tape-outs. By combining board-level software leadership with client proof points in high-frequency IC design, Keysight is...

AUSTRAC’s enforcement investigation into Western Union (WU) has put the company’s compliance framework under a spotlight, raising fresh questions for investors about regulatory risk, earnings expectations and whether the recent share price decline is justified. At a share price of $7.06, Western Union has seen the 1 month share price return rise 11.01%, even as the 1 day and 7 day share price returns declined 1.40% and 3.81% after the AUSTRAC probe and earnings concerns. Meanwhile, the 1 year...

KB Home stock has delivered a 31.4% gain over the past 5 years, yet recent declines and mixed valuation checks leave the current pricing open to interpretation for investors trying to assess whether the shares still offer value. Over 5 years, KB Home has returned 31.4%, which suggests the longer term shareholder experience has been positive even though the stock has recently pulled back. For a homebuilder like KB Home, expectations for housing demand and the company’s ability to protect...

Acushnet Holdings (GOLF) has drawn investor attention after a sharp share price decline of about 15% over the past month, prompting fresh questions on how the golf equipment group is currently valued. While Acushnet Holdings’ share price is down about 15% over the past month, the year-to-date share price return of 4.6% and a 1-year total shareholder return of 15.91% suggest longer term holders have still seen gains. As a result, the recent pullback points more to fading short term momentum...

CME Group (CME) has caught investor attention after announcing plans to launch E-mini Equity Factor futures, pending regulatory review. These contracts target growth, value, quality, momentum, low volatility and dividend-focused equity strategies. The planned E-mini Equity Factor futures arrive after a series of new contracts in areas like wind power and U.S. zinc. They come at a time when CME Group’s share price has gained 13.38% over 90 days and its 1-year total shareholder return is...

Photronics earnings event and why it matters now Photronics (PLAB) has drawn investor attention after reporting third quarter results and updating guidance for the fourth quarter of fiscal 2026. The new numbers give you fresh detail on revenue, profitability and near term expectations. Despite the stronger third quarter earnings update and fresh guidance, Photronics’ share price has eased recently, with a 7 day share price return of down 6.8% and a 30 day share price return of down 9.8%. The...

Archer-Daniels-Midland (ADM) stock is in focus after the company outlined about $100 million of capacity upgrades at four U.S. oilseed-crushing plants and raised its full-year 2026 adjusted earnings guidance. The latest capacity plans and higher 2026 earnings guidance have arrived alongside a strong run in Archer-Daniels-Midland’s stock, with the share price at $84.55 and a year-to-date share price return of 43.18%, while the 1-year total shareholder return of 40.24% points to momentum that...

In late August 2026, Jazz Pharmaceuticals reported second interim Phase 3 HERIZON-GEA-01 data and confirmed prior US FDA approvals showing that Ziihera (zanidatamab-hrii), in combinations with chemotherapy with or without Tevimbra (tislelizumab), delivered statistically significant overall survival gains over trastuzumab-based regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma. By securing US approval for the first bispecific HER2-targeted antibody plus PD-1...

Recently, analysts highlighted that AppFolio is expected to deliver earnings per share growth of about 30.6% this year, alongside upward revisions to current-year earnings estimates and a strong Zacks Rank, signaling improving expectations for its financial performance. This combination of faster expected earnings growth than the wider industry and more optimistic analyst forecasts adds weight to the view that AppFolio’s underlying business momentum is strengthening. We’ll now examine how...